Inventor · disambiguated record
Kevin Sprott
Also filed as: SPROTT KEVIN · SPROTT KEVIN T · SPROTT KEVIN TYLER
30 granted patents·29 pending applications·132 citations·filing 2000–2025
96Inventor score
Files withSYROS PHARMACEUTICALS INC23AVILAR THERAPEUTICS INC10MILLENNIUM PHARM INC4SPROTT KEVIN4DANA FARBER CANCER INST INC2
Top patents by PatentIndex Score
59 records- 0196US11819551B2ASGPR-binding compounds for the degradation of extracellular proteinsAVILAR THERAPEUTICS INC·Filed 2022·Granted Nov 21, 2023·10 cites·30 claims
- 0293US11040957B2Heteroaromatic compounds useful for the treatment of proliferative diseasesSYROS PHARMACEUTICALS INC·Filed 2018·Granted Jun 22, 2021·7 cites·21 claims
- 0392US10336760B2Inhibitors of cyclin-dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2015·Granted Jul 2, 2019·11 cites·21 claims
- 0492US10059690B2Inhibitors of cyclin-dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2017·Granted Aug 28, 2018·9 cites·19 claims
- 0591US10047070B2Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)DANA FARBER CANCER INST INC·Filed 2014·Granted Aug 14, 2018·17 cites·19 claims
- 0690US7504508B2PGD2 receptor antagonists for the treatment of inflammatory diseasesMILLENNIUM PHARM INC·Filed 2005·Granted Mar 17, 2009·14 cites·2 claims
- 0789US12290568B2ASGPR-binding compounds for the degradation of extracellular proteinsAVILAR THERAPEUTICS INC·Filed 2024·Granted May 6, 2025·1 cites·30 claims
- 0889US12280116B2ASGPR-binding compounds for the degradation of extracellular proteinsAVILAR THERAPEUTICS INC·Filed 2024·Granted Apr 22, 2025·1 cites·30 claims
- 0988US12128106B2ASGPR-binding compounds for the degradation of extracellular proteinsAVILAR THERAPEUTICS INC·Filed 2024·Granted Oct 29, 2024·1 cites·5 claims
- 1086US12312340B2Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteinsAVILAR THERAPEUTICS INC·Filed 2024·Granted May 27, 2025·0 cites·11 claims
- 1186US10308648B2Inhibitors of cyclin-dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2015·Granted Jun 4, 2019·6 cites·20 claims
- 1285US10106526B2Inhibitors of cyclin-dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2015·Granted Oct 23, 2018·5 cites·19 claims
- 1384US10906889B2Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)DANA FARBER CANCER INST INC·Filed 2018·Granted Feb 2, 2021·4 cites·32 claims
- 1484US10519135B2Inhibitors of cyclin-dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2018·Granted Dec 31, 2019·3 cites·18 claims
- 1583US2025339541A1Asgpr-binding compounds for the degradation of extracellular proteinsAVILAR THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1682US12091402B2Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteinsAVILAR THERAPEUTICS INC·Filed 2023·Granted Sep 17, 2024·0 cites·29 claims
- 1781US2025213699A1Asgpr-binding compounds for the degradation of extracellular proteinsAVILAR THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1880US8884020B2Indole compoundsTALLEY JOHN JEFFREY·Filed 2007·Granted Nov 11, 2014·11 cites·18 claims
- 1979US11124527B2Compounds for the modulation of Myc activitySYROS PHARMACEUTICALS INC·Filed 2016·Granted Sep 21, 2021·2 cites·30 claims
- 2079US10865206B2Inhibitors of cyclin-dependent kinase 7 (CDK7)SYROS PHARMACEUTICALS INC·Filed 2019·Granted Dec 15, 2020·1 cites·25 claims
- 2179US7211672B2PGD2 receptor antagonists for the treatment of inflammatory diseasesMILLENNIUM PHARM INC·Filed 2003·Granted May 1, 2007·12 cites·21 claims
- 2276US2025223280A1Potent asgpr-binding compounds for the degradation of immunoglobulins and other proteinsAVILAR THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2375US8674115B2CRTH2 modulatorsMERMERIAN ARA·Filed 2010·Granted Mar 18, 2014·8 cites·42 claims
- 2473US12076408B2ASGPR-binding compounds for the degradation of extracellular proteinsAVILAR THERAPEUTICS INC·Filed 2023·Granted Sep 3, 2024·0 cites·26 claims
- 2572US8067415B2Compounds useful as antagonists of CCR2ELDER AMY M·Filed 2006·Granted Nov 29, 2011·3 cites·26 claims
- 2672US2021107912A1Inhibitors of cyclin-dependent kinase 7 (cdk7)SYROS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2772US2024360165A1Inhibitors of cyclin dependent kinase 7 (cdk7)SYROS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2871US7960544B2Useful indole compoundsIRONWOOD PHARMACEUTICALS INC·Filed 2006·Granted Jun 14, 2011·1 cites·34 claims
- 2971US2021221814A1Inhibitors of cyclin-dependent kinase 7 (cdk7)SYROS PHARMACEUTICALIS INC·Filed 2020·Application pending·0 cites
- 3071US2023144106A1Compounds for the modulation of myc activitySYROS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3169US9657012B2FAAH inhibitorsHUDSON COLLEEN·Filed 2011·Granted May 23, 2017·3 cites·4 claims
- 3265US2021061803A1Inhibitors of cyclin-dependent kinase 7 (cdk7)SYROS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3365US2020010473A1Inhibitors of cyclin-dependent kinase 7 (cdk7)SYROS PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3465US2019330218A1Inhibitors of cyclin-dependent kinase 7 (cdk7)SYROS PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3563US11753418B2Compounds for the modulation of Myc activitySYROS PHARMACEUTICALS INC·Filed 2021·Granted Sep 12, 2023·0 cites·30 claims
- 3662US2021188833A1Compounds for the modulation of myc activitySYROS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3761US2023062491A1Inhibitors of cyclin dependent kinase 7 (cdk7)SYROS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3860US2016264551A1Heteroaromatic compounds useful for the treatment of prolferative diseasesSYROS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3959US2025282783A1Protein stabilizing compounds containing usp28 and/or usp25 targeting ligandsSTABLIX INC·Filed 2022·Application pending·0 cites
- 4059US2021221820A1Compounds for the modulation of myc activitySYROS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 4158US2024358842A1Protein stabilizing compounds containing usp7 ligandsSTABLIX INC·Filed 2022·Application pending·0 cites
- 4255US10787444B2Compounds for the modulation of myc activitySYROS PHARMACEUTICALS INC·Filed 2016·Granted Sep 29, 2020·0 cites·25 claims
- 4355US6420586B1Amino acid-derived cyclic phosphonamides and methods of synthesizing the sameUNIV KANSAS·Filed 2000·Granted Jul 16, 2002·2 cites·3 claims
- 4453US2016264552A1Heteromaromatic compounds useful for the treatment of prolferative diseasesSYROS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 4552US2009181966A1PGD2 receptor antagonists for the treatment of inflammatory diseasesMILLENNIUM PHARM INC·Filed 2009·Application pending·0 cites
- 4651US2019292167A1Heteroaromatic compounds useful for the treatment of proliferative diseasesSYROS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 4751US2006106061A1PGD2 receptor antagonists for the treatment of inflammatory diseasesMILLENNIUM PHARM INC·Filed 2005·Application pending·0 cites
- 4849US2009118503A1Faah inhibitorsSPROTT KEVIN·Filed 2008·Application pending·0 cites
- 4948US8067457B2Compounds useful as antagonists of CCR2GHOSH SHOMIR·Filed 2006·Granted Nov 29, 2011·0 cites·30 claims
- 5046US11274103B2Compounds for the modulation of MYC activitySYROS PHARMACEUTICALS INC·Filed 2017·Granted Mar 15, 2022·0 cites·24 claims
Showing the top 50 of 59 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →